Michael Makris/LinkedIn
Feb 25, 2026, 16:34
Michael Makris: Biomarin Has Decided to Withdraw Roctavian from the Market
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared on LinkedIn:
”IMPORTANT.
Biomarin has decided to withdraw Roctavian, the only approved Haemophilia A gene therapy, from the market.
Biomarin announced several months ago that it wanted to sell Roctavian to another company, but since they failed to find a buyer, they made the decision to voluntarily withdraw Roctavian from the market.
The problem was not that this did not work, but rather that there are a lot of other highly effective choices for haemophilia A subjects available.”
Stay updated with Hemostasis Today.
-
Sep 1, 2026, 02:41Richard Buka: Win a Trip to ASH or ISTH 2027
-
Sep 1, 2026, 02:38Christian’s Journey to Stability on Avatrombopag – ITP Support Association
-
Sep 1, 2026, 02:35Alexis Guédon: Is IL-6 Pathway Inhibition Reduce Cardiovascular Risk in Giant Cell Arteritis?
-
Aug 31, 2026, 17:11Chokri Ben Lamine: Early Recognition and Immediate Treatment of Catastrophic APS
-
Aug 31, 2026, 17:06Nikolaos Ktenopoulos: COMPASS-ARTeCAT Trial Highlights Arterial Thrombosis in Patients With Cancer
-
Aug 31, 2026, 17:01Mark Kaplan: Same LDL-C, Different Coagulation, Different Outcomes, in FH
-
Aug 31, 2026, 16:55Kemal Karaagac: Milvexian Did Not Reduce Ischemic Events but Did Not Increase Fatal Bleeding
-
Aug 31, 2026, 16:47Improving Outcomes in AF-Related Stroke Beyond Anticoagulation at ESC 2026 – ESO
-
Aug 31, 2026, 16:39Shariq Shamim: Are We Going to Start DOAC post TAVI not DAPT?